Radiolabeled medication is widely used in the assessment of human ADME and also increasingly in assessing absolute bioavailability (BA). Conducting an ADME study early in the clinical development program—generally before or in parallel with Phase IIa—is prudent since the outcome may generate the need for additional toxicology studies.

Register to download

Human ADME Studies With Radiolabeled Compounds Phase I-IIa

You may also be interested in: